Spotlight
Topic
Brand Insights
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Almac Group Announces Support of Agios' PYRUKYND®
Almac Group confirms it has supported Agios Pharmaceuticals, Inc., in the clinical trial and commercial launch of PYRUKYND® (mitapivat).
The treatment is the first FDA approved, disease-modifying therapy for adults with hemolytic anemia caused by PK deficiency, a rare, debilitating, and lifelong form of anemia.
Read more about the work between Almac Group and Agios here.
Related Videos
Related Content
Fierce Females in the Life Science Space
March 29th 2024Podcast
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
